Company intelligence / Profile preview

Voyageur Pharmaceuticals Ltd.

Calgary, Alberta, Canadavoyageurpharmaceuticals.ca ↗

Ownership: Private
Development stage: Commercial

Overview

Voyageur has begun human testing of its barium contrast product line in January 2025, with phase one focusing on Canadian radiology centers for domestic market entry later in 2025. Phase two will gather data under FDA guidelines to secure U.S. licensing[5].

Therapeutic areas: OtherGastroenterologyInfectious Diseases
Modalities: Contrast media productsActive Pharmaceutical Ingredients (APIs)
Industry: Biotech

Drug pipeline

5 assets

iodine

4 more assets in the full pipeline.

Request access →

Partnerships

Applied Pharmaceutical Innovation (API)Rain Cage Carbon Inc.Unnamed multinational contrast media company (LOI signed)[5][7]

Beyond the preview

Go deeper on Voyageur Pharmaceuticals Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Voyageur Pharmaceuticals Ltd..

Explore the full profile